Harrow (NASDAQ:HROW) Reaches New 52-Week High at $38.38

Shares of Harrow, Inc. (NASDAQ:HROW) reached a new 52-week high on Wednesday . The company traded as high as $38.38 and last traded at $37.85, with a volume of 29165 shares trading hands. The stock had previously closed at $37.85.

Analysts Set New Price Targets

Several research firms recently issued reports on HROW. Craig Hallum increased their target price on shares of Harrow from $30.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 9th. B. Riley lifted their target price on Harrow from $29.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Lake Street Capital upped their price target on Harrow from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, June 3rd.

Harrow Trading Up 0.5 %

The stock has a market cap of $1.35 billion, a PE ratio of -41.63 and a beta of 0.77. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.43 and a current ratio of 2.60. The stock has a fifty day moving average price of $22.53 and a 200 day moving average price of $15.80.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.03). Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. The firm had revenue of $34.59 million for the quarter, compared to analysts’ expectations of $34.37 million. Equities analysts expect that Harrow, Inc. will post -0.51 EPS for the current year.

Institutional Trading of Harrow

Several institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of Harrow during the second quarter worth $33,000. Allspring Global Investments Holdings LLC increased its stake in Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after buying an additional 2,048 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Harrow by 66.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,745 shares of the company’s stock worth $89,000 after buying an additional 2,682 shares during the period. Bayesian Capital Management LP bought a new stake in Harrow during the 1st quarter valued at about $185,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Harrow by 6.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock valued at $221,000 after buying an additional 1,033 shares during the period. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.